<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20160307026950N48</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-12-11</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>The effect of Atracurium and Cis-Atracurium injection on hemodynamic status and Neutrophil-to-Lymphocyte Ratio (NLR) during anesthesia induction</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of Atracurium and Cis-Atracurium injection on hemodynamic status and Neutrophil-to-Lymphocyte Ratio (NLR) during anesthesia induction</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-11-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/66985</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Diagnostic, Randomization description: This is a simple randomized clinical trial that patients are divided into groups based on flipping a coin; After the first flip of the coin, for the first patient, atracurium is selected for injection in the case of heads, and in the case of tails, cis atracurium is selected. Then, from the second patient onwards, individuals enter the groups one by one until the number reaches 40 people in each group, Blinding description: This is a double-blind clinical trial so that, before obtaining consent, the patients will be informed of the study but will not be informed about the type of intervention received. Also, the researchers responsible for collecting and analyzing the data won't be informed about the intervention group; therefore, they are all blind.</study_design>
      <phase>2</phase>
      <hc_freetext>Change in hemodynamic status and NLR.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group A: In this group, after placing the patients on the surgical bed and connecting the monitoring and establishing two suitable intravenous lines, the first venous blood sample is taken for cell counting and the patient's initial clinical symptoms are measured and recorded. Then, 5 mg/kg Sodium Thiopental made by Elixir Pharmaceutical Company, 100 micrograms of Fentanyl made by Caspin Pharmaceutical Company and 0.5 mg/kg of Atracurium made by Aburihan Pharmaceutical Company are injected to induce anesthesia. Sampling and recording of symptoms are also done in 3, 10 and 20 minutes after anesthesia. Intervention 2: Intervention group B: In this group, after placing the patients on the surgical bed and connecting the monitoring and establishing two suitable intravenous lines, the first venous blood sample is taken for cell counting and the patient's initial clinical symptoms are measured and recorded. Then, 5 mg/kg Sodium Thiopental made by Elixir Pharmaceutical Company, 100 micrograms of Fentanyl made by Caspin Pharmaceutical Company and 0.15 mg/kg of Cis-Atracurium made by Aburihan Pharmaceutical Company are injected to induce anesthesia. Sampling and recording of symptoms are also done in 3, 10 and 20 minutes after anesthesia.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Behzad Nazem roaya</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hezar Jarib</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8146713543</zip>
        <telephone>+98 31 3620 2020</telephone>
        <email>behzad_nazem@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Behzad Nazem roaya</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hezar Jarib</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8146713543</zip>
        <telephone>+98 31 3620 2020</telephone>
        <email>behzad_nazem@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients 18 to 65 years old
Anesthesia class I and II according to ASA criteria
Candidate for anesthesia with Atracurium and Cis-Atracurium
Informed consent to enter the study</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Obesity or BMI (Body Mass Index) of more than 30
History of cardiovascular diseases and hemodynamic disorders or myocardial infarction in the last 6 months
Taking psychoactive drugs, antihistamines and corticosteroids in the last week
Addiction to opioid and non-opioid drugs
Pregnancy and breastfeeding
Having diabetes, orthostatic hypotension, bradycardia, hypokalemia, hypothyroidism, depression, long QT syndrome, asthma and allergies</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Diagnosis</i_code>
      <i_code>Diagnosis</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group A: In this group, after placing the patients on the surgical bed and connecting the monitoring and establishing two suitable intravenous lines, the first venous blood sample is taken for cell counting and the patient's initial clinical symptoms are measured and recorded. Then, 5 mg/kg Sodium Thiopental made by Elixir Pharmaceutical Company, 100 micrograms of Fentanyl made by Caspin Pharmaceutical Company and 0.5 mg/kg of Atracurium made by Aburihan Pharmaceutical Company are injected to induce anesthesia. Sampling and recording of symptoms are also done in 3, 10 and 20 minutes after anesthesia.</i_keyword>
      <i_keyword>Intervention group B: In this group, after placing the patients on the surgical bed and connecting the monitoring and establishing two suitable intravenous lines, the first venous blood sample is taken for cell counting and the patient's initial clinical symptoms are measured and recorded. Then, 5 mg/kg Sodium Thiopental made by Elixir Pharmaceutical Company, 100 micrograms of Fentanyl made by Caspin Pharmaceutical Company and 0.15 mg/kg of Cis-Atracurium made by Aburihan Pharmaceutical Company are injected to induce anesthesia. Sampling and recording of symptoms are also done in 3, 10 and 20 minutes after anesthesia.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Heart Rate. Timepoint: before induction of anesthesia and at 3, 10, and 20 minutes after anesthesia. Method of measurement: Electrocardiogram.</prim_outcome>
      <prim_outcome>Blood Pressure. Timepoint: before induction of anesthesia and at 3, 10, and 20 minutes after anesthesia. Method of measurement: Sphygmomanometer.</prim_outcome>
      <prim_outcome>Oxygen saturation. Timepoint: before induction of anesthesia and at 3, 10, and 20 minutes after anesthesia. Method of measurement: Pulse Oximeter.</prim_outcome>
      <prim_outcome>Neutrophil to lymphocyte ratio. Timepoint: before induction of anesthesia and at 3, 10, and 20 minutes after anesthesia. Method of measurement: Cell count of venous blood sample.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-09-11</approval_date>
        <contact_name>Ethics Committee in Biomedical Research, Isfahan University of Medical Sciences</contact_name>
        <contact_address>Hezar Jarib St Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
